JAZZ - Jazz Pharmaceuticals plc

NasdaqGS - NasdaqGS Real-time price. Currency in USD
163.54
+1.03 (+0.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close163.31
Open163.67
Bid161.00 x 800
Ask175.87 x 800
Day's range162.18 - 165.22
52-week range128.58 - 184.00
Volume376,161
Avg. volume436,553
Market cap9.879B
Beta1.19
PE ratio (TTM)23.07
EPS (TTM)7.09
Earnings date5 Nov 2018 - 9 Nov 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est195.00
Trade prices are not sourced from all markets
  • Is Jazz Pharmaceuticals a Great Stock for Value Investors?
    Zacks6 days ago

    Is Jazz Pharmaceuticals a Great Stock for Value Investors?

    Let's see if Jazz Pharmaceuticals (JAZZ) stock is a good choice for value-oriented investors right now from multiple angles.

  • Is the Options Market Predicting a Spike in Jazz Pharmaceuticals (JAZZ) Stock?
    Zacks6 days ago

    Is the Options Market Predicting a Spike in Jazz Pharmaceuticals (JAZZ) Stock?

    Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.

  • Why Is Jazz (JAZZ) Down 2.4% Since Last Earnings Report?
    Zacks20 days ago

    Why Is Jazz (JAZZ) Down 2.4% Since Last Earnings Report?

    Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Is Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) PE Ratio A Signal To Buy For Investors?
    Simply Wall St.27 days ago

    Is Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) PE Ratio A Signal To Buy For Investors?

    The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to begin learning about how toRead More...

  • Jazz Pharmaceuticals’ Vyxeos Approved for EU Commercialization
    Market Realistlast month

    Jazz Pharmaceuticals’ Vyxeos Approved for EU Commercialization

    Today, the European Commission (or EC) approved the marketing authorization of Jazz Pharmaceuticals’ (JAZZ) Vyxeos. This authorization covers the treatment of adult individuals with newly diagnosed treatment-associated acute myeloid leukemia with myelodysplasia-related changes (or AML-MRC).

  • Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
    Zackslast month

    Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe

    Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.

  • Investor's Business Dailylast month

    These Five 95+ Composite Rating Stocks Are Just Below Buy Points

    Five top stocks with IBD Composite Ratings of 95 or higher are closing in on buy points: Urban Outfitters, Veeva Systems, Copart, Automatic Data Processing and Jazz Pharmaceuticals.

  • Endo International Has Raised Its Earnings Guidance for 2018
    Market Realist2 months ago

    Endo International Has Raised Its Earnings Guidance for 2018

    In its Q2 2018 earnings conference call, Endo International (ENDP) raised its 2018 adjusted EBITDA guidance from $1.2 billion–$1.3 billion to $1.27 billion–$1.33 billion. It expects its adjusted gross margin to be 68.5%–69.5%, which is higher than its previously projected range of 67%–68%. Wall Street analysts have projected Endo International’s 2018 adjusted diluted EPS at $2.50, which would be a YoY decline of 34.4%.

  • Analyst Ratings for Endo International and Peers in August
    Market Realist2 months ago

    Analyst Ratings for Endo International and Peers in August

    In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY (year-over-year) decline of 18.4%. Additionally, the discontinuation of commercialization of certain generic pharmaceutical products in the US market, competitive pressures, and the divestitures of Grupo Farmacéutico Somar and Litha Healthcare Group had negative impacts on Q2 revenues. To know more about the performance of Endo International stock after its Q2 2018 earnings release, be sure to read Why Endo International Stock Soared after Q2 Results.

  • Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals
    Market Realist2 months ago

    Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals

    In August 2018, Jazz Pharmaceuticals (JAZZ) and the University of Texas MD Anderson Cancer Center entered a five-year collaboration agreement to investigate therapies for the treatment of multiple hematologic malignancies such as AML (acute myeloid leukemia) and myelodysplastic syndrome.

  • Investor's Business Daily2 months ago

    Stocks Fall As Trade War Heats Up; This Top Growth Stock Breaks Out

    The stock market was mildly lower early Wednesday, as China retaliated with new tariffs on U.S. goods. Michael Kors is breaking out today.

  • Investor's Business Daily2 months ago

    IBD 50 Stock Jazz Pharma Tops Views, But Profit Outlook Light

    Jazz Pharmaceuticals on Tuesday reported adjusted income of $3.49 per share on sales of $500 million for its second quarter.

  • How Jazz Pharmaceuticals’ Products Performed in the Second Quarter
    Market Realist2 months ago

    How Jazz Pharmaceuticals’ Products Performed in the Second Quarter

    How Did Jazz Pharmaceuticals Fare in the Second Quarter? Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $356.0 million in the second quarter of 2018, which reflected ~19% year-over-year growth and ~12% sequential growth. Jazz Pharmaceuticals anticipates Xyrem’s net revenues in fiscal 2018 to be in the range of $1.87 million and $1.91 million.

  • How Did Jazz Pharmaceuticals Perform in the Second Quarter?
    Market Realist2 months ago

    How Did Jazz Pharmaceuticals Perform in the Second Quarter?

    On August 7, Jazz Pharmaceuticals (JAZZ) released its second-quarter 2018 financial results. Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.

  • Mallinckrodt Stock Rose 20.9% on August 7
    Market Realist2 months ago

    Mallinckrodt Stock Rose 20.9% on August 7

    On August 7, Mallinckrodt (MNK) reported revenues of ~$631.7 million for the second quarter, which is ~5.3% growth YoY (year-over-year) on a reported basis and 5.0% on a constant currency basis. The company reported non-GAAP EPS of $1.78, which is a rise of 30.9% YoY. The company beat Wall Street analysts’ revenue and non-GAAP EPS estimates for the second quarter by $11.31 million and $0.30, respectively.

  • Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat
    Zacks2 months ago

    Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat

    Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q2. However, sales of its newest drug, Vyxeos disappoint. Stock down 7% in after-hours trading.

  • Associated Press2 months ago

    Jazz: 2Q Earnings Snapshot

    On a per-share basis, the Dublin-based company said it had net income of $1.50. Earnings, adjusted for one-time gains and costs, were $3.49 per share. The results exceeded Wall Street expectations. The ...

  • Investor's Business Daily2 months ago

    11 Blue Chips Drive Dow Jones Higher; How Apple Can Hit $1.25 Trillion In Market Cap

    Apple is easing after reaching the $1 trillion market-value milestone, yet remains a stock market leader and industry innovator. Tech stocks in software, hardware broke out.

  • Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?
    Zacks2 months ago

    Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?

    Jazz's (JAZZ) Xyrem will likely continue to do well in the second quarter. Supply constraints will continue to hurt sales of Erwinaze.

  • Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)
    Zacks2 months ago

    Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)

    Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

  • Investor's Business Daily2 months ago

    IBD Stock Of The Day: Jazz Pharma Approaches Buy Point Ahead Of Earnings

    Jazz Pharmaceuticals is the IBD Stock Of The Day as the pharmaceutical company approaches a buy point ahead of its second-quarter report next week. Shares are forming a flat base with a buy point at 184.10

  • These Could Be Jazz Pharmaceuticals’ Long-Term Growth Drivers
    Market Realist3 months ago

    These Could Be Jazz Pharmaceuticals’ Long-Term Growth Drivers

    In June, the FDA accepted Jazz Pharmaceuticals’ (JAZZ) supplemental new drug application (or sNDA) for the label expansion of Xyrem. Jazz Pharmaceuticals filed an sNDA for the label expansion of Xyrem for the inclusion of its use in the treatment of cataplexy and EDS (excessive daytime sleepiness) in pediatric narcolepsy patients. Jazz Pharmaceuticals’ sNDA was supported by data from the Phase 2/3 EXPRESS trial, which was conducted on pediatric patients between seven and 17 years old with narcolepsy.

  • How Jazz Pharmaceuticals Is Positioned before Its Q2 2018 Results
    Market Realist3 months ago

    How Jazz Pharmaceuticals Is Positioned before Its Q2 2018 Results

    Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million in the first quarter, reflecting an ~18% YoY (year-over-year) rise. Xyrem and Vyxeos primarily pushed the company’s revenue growth in the quarter.

  • Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
    Zacks3 months ago

    Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval

    Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.

  • Analysts Are Mostly Positive on Jazz Pharmaceuticals in July
    Market Realist3 months ago

    Analysts Are Mostly Positive on Jazz Pharmaceuticals in July

    In June, Jazz Pharmaceuticals (JAZZ) entered into an agreement with TerSera Therapeutics to sell its rights associated with Prialt to TerSera. As per the terms of the agreement, TerSera will provide employment opportunities to the majority of the Jazz Pharmaceuticals’ employees associated with Prialt. Presently, Prialt is the only therapy approved by the FDA for the treatment of chronic pain in adult individuals in need of intrathecal therapy.